Character Bio

Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology. The company's mission is to identify the genetic and molecular drivers of disease progression to develop targeted therapies for patients who urgently need them.

Character Bio has built one of the most comprehensive resources in age-related eye diseases by partnering with over 150 ophthalmology clinics to integrate genetics with longitudinal clinical and imaging data. This deep phenotyping approach enables us to reclassify complex diseases like age-related macular degeneration (AMD) into genetically defined subtypes, unlocking novel therapeutic targets and optimizing patient selection for clinical trials.

Character Bio’s platform combines genomics, deep clinical data, and AI-driven modeling to discover and develop therapies that are more precise and more effective. The company's lead programs, CTX114 and CTX203, are advancing toward clinical trials and are designed to slow or prevent vision loss in AMD patients.

Character Bio is committed to delivering a new generation of precision medicines to treat and ultimately cure age-related blindness.